Previous name: Caspofungin MSD
Active Substance: caspofungin
Common Name: caspofungin
ATC Code: J02AX04
Marketing Authorisation Holder: Merck Sharp & Dohme Ltd.
Active Substance: caspofungin
Authorisation Date: 2001-10-24
Therapeutic Area: Aspergillosis Candidiasis
Pharmacotherapeutic Group: Antimycotics for systemic use
- Treatment of invasive candidiasis in adult or paediatric patients.
- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy.
- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
What is Cancidas?
Cancidas is a powder that is made up into a solution for infusion (drip into a vein). It contains the active substance caspofungin.
What is Cancidas used for?
Cancidas is an antifungal medicine. It is used to treat adults, adolescents and children with:
- invasive candidiasis (a type of fungal infection due to Candida);
- invasive aspergillosis (another type of fungal infection due to Aspergillus) when the patient does not respond to or does not tolerate amphotericin B or itraconazole (other antifungal medicines);
- suspected fungal infections (such as due to Candida or Aspergillus) when the patient is febrile (feverish) and neutropenic (lacking white blood cells). This is known as ‘empirical treatment’, which means that the treatment is started based on an observation of the patient before the doctor has a confirmation of the infection.
The medicine can only be obtained with a prescription.
How is Cancidas used?
Cancidas treatment should be started by a doctor who has experience in the management of invasive fungal infections. Cancidas must be made up into a solution before use, using a diluent that does not contain glucose.
It is given once a day by slow infusion lasting about one hour. In adults, treatment starts with a 70-mg loading dose, followed by a daily 50-mg dose, or 70 mg if the patient weighs more than 80 kg. A lower dose may be necessary in adults who have moderate problems with their liver.
In patients between 12 months and 17 years of age, the dose depends on body surface area (calculated using the child’s height and weight). Cancidas should be used with caution in children below 12 months of age, because it has not been studied sufficiently in this age group.
Treatment is continued for up to two weeks after the infection has been cured.
How does Cancidas work?
The active substance in Cancidas, caspofungin, belongs to a group of antifungal medicines known as ‘echinocandins’. It works by interfering with the production of a component of the fungal cell wall called ‘glucan polysaccharide’, which is necessary for the fungus to continue living and growing. Fungal cells treated with Cancidas have incomplete or defective cell walls, making them fragile and unable to grow. The list of fungi against which Cancidas is active can be found in the summary of product characteristics (also part of the EPAR).
How has Cancidas been studied?
Cancidas has been studied in five main studies.
Three studies looked at the effects of Cancidas in the treatment of invasive candidiasis or aspergillosis: one study involved 239 adults with invasive candidiasis, another involved 69 adults with invasive aspergillosis, and the third involved 49 patients aged between six months and 17 years with either candidiasis or aspergillosis. Cancidas was compared with amphotericin B given into a vein in the study of adults with invasive candidiasis.
For the empirical treatment of neutropenic febrile patients, Cancidas has been compared with amphotericin B in two studies: one involving 1,111 adults and another involving 82 patients aged between two and 17 years.
In all five studies, the main measure of effectiveness was the number of patients who responded to treatment. This is based on the improvement of their symptoms, as well as other criteria, such as elimination of the fungus from samples taken from the patients.
What benefit has Cancidas shown during the studies?
In invasive candidiasis, 73% of the adults treated with Cancidas who could be assessed had a favourable response (80 out of 109), compared with 62% of the adults treated with amphotericin B (71 out of 115).
In invasive aspergillosis, 41% of the adults had a favourable response at the end of the study (26 out of 63). Of the adults who did not respond to other treatments, 36% responded to Cancidas (19 out of 53). Of those who did not tolerate other treatments, 70% responded to Cancidas (7 out of 10).
Similar responses were seen in children and adolescents: 50% of those with invasive candidiasis (5 out of 10) and 81% of those with invasive aspergillosis (30 out of 37) responded to Cancidas.
In the empirical treatment of febrile neutropenic patients, Cancidas was as effective as amphotericin B. In the adult study, 34% of both groups of adults had a favourable response. Similar results were seen in the study of children and adolescents.
What is the risk associated with Cancidas?
The most common side effect with Cancidas (seen in more than 1 patient in 10) is fever. For the full list of all side effects reported with Cancidas, see the package leaflet.
Cancidas should not be used in people who may be hypersensitive (allergic) to caspofungin or any of the other ingredients.
Why has Cancidas been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that Cancidas’s benefits are greater than its risks for the treatment of invasive candidiasis or aspergillosis, and empirical therapy for presumed fungal infections, in adult or paediatric patients. The Committee recommended that Cancidas be given marketing authorisation.
Cancidas was originally authorised under ‘exceptional circumstances’, because limited information was available at the time of approval. As the company had supplied the additional information requested, the exceptional circumstances ended on 29 September 2006.
Other information about Cancidas
The European Commission granted a marketing authorisation valid throughout the European Union for Caspofungin MSD to Merck Sharpe and Dohme Limited on 24 October 2001. The name of the medicine was changed to Cancidas on 9 April 2003. The marketing authorisation was renewed on 24 October 2006.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.